logo banner home news contact
nav
about argos
argos overview
market opportunities
leadership
current investors
partners

 

Argos Overview

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patientís dendritic cells to activate an immune response specific to the patient´s disease. Argos´ most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV.

Argos, a private biotechnology company, is headquartered in Research Triangle Park, NC. The Company has clinical trial programs in metastatic renal cell carcinoma (RCC), human immunodeficiency virus (HIV) and systemic lupus erythematosus (SLE).

Product Pipeline

View a list of upcoming conferences in which Argos will participate.